PYX-203 / Pyxis Oncology, Pfizer - LARVOL DELTA

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update (GlobeNewswire) - "Pyxis Oncology is on track to file Investigational New Drug applications (INDs) for PYX-201 and PYX-106 in 2022; The Company will pause the preclinical development of PYX-203 and PYX-102."

IND • Preclinical • Oncology

Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) - "Pyxis Oncology, Inc...today reported financial results for its first quarter ended March 31, 2022. The Company ended the quarter with approximately $247 million in cash and cash equivalents. Pyxis Oncology remains on target to file INDs for anti-EDB, PYX-201, and anti-Siglec-15, PYX-106, in the second half of 2022 and INDs for anti-CD123, PYX-203, and anti-KLRG1, PYX-102, in the second half of 2023. Further, as previously disclosed, the Company expects to provide an update on its anti-DLK1 ADC, PYX-202, in mid-2022."

IND • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Lung Cancer • Melanoma • Merkel Cell Carcinoma • Non Small Cell Lung Cancer • Non-melanoma Skin Cancer • Oncology • Ovarian Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer • Triple Negative Breast Cancer • Uterine Cancer

Pyxis Oncology Provides Corporate and Financial Update (GlobeNewswire) - "The American Academy for Cancer Research (AACR) has accepted an abstract submitted by Biosion for PYX-106. The poster will be made available at the start of the AACR Annual Meeting on April 8, 2022....The Company will continue to monitor the progress of its PYX-202 program and expects to provide an update about PYX-202 in mid-2022....Pyxis Oncology expects to file INDs for anti-EDB, PYX-201, and anti-CD123, PYX-203, in the second half of 2022 and in the second half of 2023, respectively."

Preclinical • Oncology • Solid Tumor

Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update (GlobeNewswire) - "R&D expenses were $7.8 million for the three months ended September 30, 2021, compared to $2.4 million for the three months ended September 30, 2020."

Commercial • Hematological Malignancies • Oncology • Solid Tumor

Pyxis Oncology: Pfizer Backed UoC Spinout Files For IPO (SeekingAlpha) - "The Company plans to develop PYX-201 initially for the treatment of non-small cell lung cancer (‘NSCLC), and submit an investigational new drug (‘IND) application by mid-2022. IP protection runs through 2037...The Company plans to submit an IND for PYX-202 by mid-2022. IP protection runs through 2040....The Company believes a larger patient population including those who do not respond to standard of care (‘SoC) may benefit from PYX-203, and plans to submit an IND by 2023. IP protection runs through 2038."

Financing • IND • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential (GlobeNewswire) - “Pyxis Oncology…announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the potential of its ADC platform. The Company will host a webcast with KOLs to further discuss the potential of Pyxis’ ADCs to improve the lives of patients with difficult-to-treat cancers…All three candidates are potent with highly stable linker-payload conjugation – characteristics that have led to superior therapeutic indexes...‘We look forward to progressing our ADC candidates to IND submissions next year.”

IND • Preclinical • Oncology

Pyxis Oncology Hosting Key Opinion Webinar on Antibody-Drug Conjugates (GlobeNewswire) - "Pyxis Oncology...announced that it will host a key opinion leader (KOL) webinar on antibody-drug conjugates on Tuesday, April 27, 2021 at 1pm Eastern Time....Pyxis is currently advancing three ADC candidates: PYX-201, PYX-202, and PYX-203. All three candidates leverage site-specific conjugation technology to improve these drugs' stability and activity and target both novel and established tumor antigens. PYX-201 and PYX-202 candidates also have local immuno-modulatory effects and may act synergistically in a combination treatment setting with immunotherapies....PYX-203 targets an antigen expressed in certain hematologic malignancies and utilizes a highly potent DNA-damaging agent designed to reduce the potential development of drug resistance and disease relapse."

Clinical • Oncology • Solid Tumor

Pyxis’s $152m Series B Will Push Trio Of ADCs Toward Clinic (Scripintelligence) - "Pyxis says its three preclinical ADCs...will reach Phase I in 2022."

Financing • New P1 trial • Oncology

Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics - "Pyxis Oncology...announced the closing of a $152 million Series B financing, led by Arix Bioscience and co-led by RTW Investments, LP, with participation from additional new investors, including Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital (a Citadel company), Laurion Capital Management, Logos Capital, and LifeSci Venture Partners. This round brings Pyxis' total funding to $174 million....Pyxis will use the proceeds from the financing to advance its differentiated portfolio of ADCs, a growing class of therapies that deliver highly potent targeted treatments directly to cancer cells, including PYX-201 and PYX-203, both in-licensed from Pfizer, and PYX-202, recently in-licensed from LegoChem Biosciences."

Financing • Hematological Malignancies • Oncology

Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates (GlobeNewswire) - "Pyxis Oncology...announced that it has entered into a worldwide license agreement with Pfizer Inc...for the development and commercialization of two antibody-drug conjugate (ADC) candidates and a license to Pfizer’s ADC technology platform, enabling expansion of its ADC portfolio and further strengthening its developmental capabilities...Under the terms of the licensing agreement, Pfizer will provide Pyxis with a worldwide, royalty-bearing license to develop and commercialize two innovative ADC candidates, PYX-201 and PYX-203....PYX-201 is a first-in-class non-internalizing ADC that targets a tumor-restricted antigen that is overexpressed in several solid tumor types to selectively kill tumor cells while enhancing a robust anti-cancer immune response. PYX-203 is an ADC that targets an antigen expressed in certain hematologic malignancies."

Licensing / partnership • Hematological Malignancies • Oncology